EPZ020411, a PRMT6 inhibitor, suppresses colorectal cancer cell proliferation, migration, and invasion through targeting the TGM2/MAPK axis

Figure 3 EPZ020411 inhibits transglutaminase 2 gene expression and suppresses the JNK and p38 signaling pathways. A and B: The heatmap of RNA sequencing displays the differentially expressed genes in HCT116 cells treated with EPZ020411; C and D: Reverse transcription-quantitative polymerase chain reaction was used to detect the expression levels of transglutaminase 2 (TGM2) mRNA in EPZ020411-treated HCT116 and CACO-2 cells; E and F: Western blot was used to detect the expression levels of TGM2 protein in EPZ020411-treated HCT116 and CACO-2 cells; G and H: Western blot analysis of JNK, p-JNK, p38 and p-p38 protein levels in HCT116 and CACO-2 cells treated with varying concentrations of EPZ020411. Data are presented as mean ± SD from three independent experiments (n = 3). Error bars represented the mean ± SEM. ^aP < 0.01, ^bP < 0.001. TGM2: Transglutaminase 2.